Chemours (NYSE:CC) Now Covered by Truist Financial

Truist Financial assumed coverage on shares of Chemours (NYSE:CC) in a report issued on Tuesday, Marketbeat.com reports. The brokerage issued a buy rating and a $27.00 target price on the specialty chemicals company’s stock.

CC has been the topic of several other reports. Morgan Stanley dropped their price objective on Chemours from $25.00 to $22.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Royal Bank of Canada reiterated an “outperform” rating and issued a $25.00 price target on shares of Chemours in a research note on Thursday, December 12th. The Goldman Sachs Group lowered their price objective on shares of Chemours from $24.00 to $21.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 7th. Barclays lifted their target price on shares of Chemours from $21.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Finally, Mizuho lowered their price target on Chemours from $22.00 to $21.00 and set a “neutral” rating on the stock in a report on Tuesday, January 7th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Chemours presently has an average rating of “Hold” and a consensus target price of $24.11.

Chemours Stock Up 2.0 %

NYSE:CC opened at $19.34 on Tuesday. The company has a debt-to-equity ratio of 6.05, a quick ratio of 0.92 and a current ratio of 1.73. The firm has a market cap of $2.89 billion, a P/E ratio of 38.67 and a beta of 1.83. Chemours has a fifty-two week low of $15.10 and a fifty-two week high of $31.76. The firm has a 50-day simple moving average of $19.14 and a two-hundred day simple moving average of $19.54.

Chemours (NYSE:CC) last announced its quarterly earnings data on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.32 by $0.08. Chemours had a net margin of 1.34% and a return on equity of 29.48%. The company had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.44 billion. During the same period in the previous year, the business earned $0.64 EPS. The firm’s revenue for the quarter was up .9% on a year-over-year basis. Analysts predict that Chemours will post 1.19 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Chemours news, SVP Alvenia Scarborough sold 7,500 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $20.64, for a total transaction of $154,800.00. Following the completion of the sale, the senior vice president now directly owns 16,645 shares of the company’s stock, valued at $343,552.80. This trade represents a 31.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.47% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Chemours

Hedge funds and other institutional investors have recently modified their holdings of the stock. KBC Group NV lifted its stake in Chemours by 19.5% in the 3rd quarter. KBC Group NV now owns 4,468 shares of the specialty chemicals company’s stock worth $91,000 after purchasing an additional 728 shares in the last quarter. Blue Trust Inc. increased its holdings in shares of Chemours by 166.9% in the third quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company’s stock worth $26,000 after purchasing an additional 731 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Chemours by 99.7% in the fourth quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company’s stock worth $26,000 after buying an additional 765 shares in the last quarter. ARGA Investment Management LP boosted its stake in Chemours by 0.7% during the fourth quarter. ARGA Investment Management LP now owns 148,614 shares of the specialty chemicals company’s stock valued at $2,512,000 after buying an additional 1,032 shares during the last quarter. Finally, State of Alaska Department of Revenue grew its holdings in Chemours by 7.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 17,205 shares of the specialty chemicals company’s stock valued at $349,000 after buying an additional 1,175 shares in the last quarter. Institutional investors own 76.26% of the company’s stock.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.